Onconetix presents Proclarix data at EAU; 96% sensitivity, 22% biopsy avoidance in Danish cohort

Onconetix, Inc.

Proclarix evaluated in 808 patients; in targeted subpopulation (n=371), negative test gave 5% csPCa probability vs 14% for %fPSA (p=0.028).
Proclarix avoided 22% of biopsies while missing only 3 of 101 csPCa cases (2 GG2, 1 GG3).
In extended population (n=654, PSA 2-20 ng/mL), sensitivity 96%, specificity significantly higher than %fPSA and ERSPC RC (p<0.001).
Data presented March 23, 2025 at EAU congress in Madrid; study led by Ahmed H. Zedan, MD, PhD of Lillebaelt Hospital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.